Sign up
Pharma Capital

Regeneus shares rise as results show Sygenus gel successfully fights acne

In a tough day across the ASX last Tuesday, Regeneus shares were up 14% to $0.12.
Girl popping pimple
Regeneus has patents in Australia, Europe, China, Japan and the US

Regeneus Ltd (ASX:RGS) has received promising results indicating that the topical use of Sygenus gel for six weeks in adults with acne was well tolerated.

The study also showed a significant effect on the appearance of acne lesions as early as three weeks.

Sygenus is a patented allogeneic cell secretions technology platform that comprises cytokines, growth factors and exosomes from adipose-derived mesenchymal stem cells.

Bioactive molecules reduce pain and inflammation

Bioactive molecules work to reduce pain and inflammation and encourage accelerated healing and repair.

The tolerance study, performed by RCTS, a dermatology testing company in Texas, examined the tolerability of Sygenus in 33 healthy volunteers with mild to moderate facial acne.

The study endpoints to assess tolerability involved the change in acne lesions over the 6-week period when Sygenus gel was applied topically twice a day.

Overall improvement achieved as early as three weeks

No intolerance was observed and there was an overall improvement in the appearance of acne, as early as 3 weeks.

Statistically significant reductions in the total number of inflammatory and non-inflammatory acne lesions were noted from baseline to week 6.

The acne global severity score also showed significant reduction (improvement) at week 6 compared to baseline.

Strong demand for new acne treatments

These promising results will help in the partnering of Sygenus gel for the acne market and other inflammatory skin conditions.

With few treatment innovations or improvements without significant side effects in the treatment of acne over the last 10 years, the demand for improved acne treatments is high.

Regeneus has patents in Australia, Europe, China, Japan and the US covering the composition, manufacture and use of Sygenus technology for the topical treatment of acne.

The company also has patent applications for the use of Sygenus for a broad range of other inflammatory skin conditions.

Potential pain relief applications

A key area of research focus is the use of Sygenus technology for the treatment of pain.

A preclinical post-operative pain study has shown that topical application of Sygenus has significant and longer lasting analgesic effects than an injection of morphine.

READ: Regeneus finds impressive pain relief properties in Sygenus

Regeneus is also investigating the use of its stem cell technologies for the treatment of pain in an ARC Linkage program with the University of Adelaide and Macquarie University.

View full RGS profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.